Loroblis – the ally of the parents in the fight with betahemolytic streptococcus group A.
If you are a parent, you certainly associate the cold season with the days when you have to be absent from work to take your little one to the doctor or with the forced holidays, when the child cannot go to school because he feels too bad.
Winter is the time when the little ones are upset at home, when they can’t drink water and can’t eat because of sore throats. Then the incidence of respiratory infections – pharyngitis, tonsillitis, acute otitis media – due to beta-hemolytic streptococcus group A (Streptococcus pyogenes) and not only, increases significantly, threatening, in particular, children aged 3 to 14 years. This segment represents almost 11% of the number of microbe carriers.
Group A beta-hemolytic streptococcus is easily transmitted by sneezing, coughing, runny nose or even coming into contact with contaminated objects (furniture, toys, books, etc.), which means that in schools, its rate of spread is very big.
It is no wonder that schools and kindergartens are turning into real hotbeds of epidemics for children and that visits to the doctor become a winter tradition strictly respected. However, clinical trials show that treatment with Streptococcus salivarius K12, also known as Blis K12, the major component of Loroblis orodispensible supplements, may be the best solution to prevent recurrent pharyngeal and oral streptococcal disease, and thus save families. who want to enjoy the cold season together. What is Blis K12? A bacterial strain that is found in the oral and nasopharyngeal cavities when we are healthy, and which provides natural protection of the upper respiratory tract.
Especially in children, the absence of Blis K12 increases by up to 200% the chance of getting B-hemolytic group A streptococcus disease.
What does medical research support? In early 2016, a study by Dr. Francesco di Piero of the University of Parma examined the role of Blis K12 in controlling streptococcal disease and acute otitis media among children in the first year of kindergarten, showing that the administration reduces the risk of disease.
In the study, 222 children were divided into 2 equal groups: the treatment group – which received Blis K12 – and the control group – which did not receive the active substance. During the 6-month administration period, the incidence of streptococcal pharyngotonsillitis and acute otitis media was approximately 16% and 44%, respectively, among children who received treatment, significantly lower than in the group of untreated children, where the rate of reached 48% and 80%, respectively.
Moreover, even in the first 3 months of follow-up, children receiving Blis K12 treatment had fewer episodes of streptococcal infection and otitis media (15% and 12%) compared with placebo-treated children. (26% and 36%). During the 3 months of follow-up, the incidence of streptococcal disease and otitis media was 15% and 12% among patients who received treatment, compared with 26% and 36% in the untreated group, showing that daily administration of Loroblis is associated with a significant reduction in the rate of illness, since entering the community.
Moreover, a new research conducted by the same Dr. Francesco di Piero and published in late November 2016, supports the protective effects of Blis K12 in relation to a number of streptococcal and non-streptococcal infections, even after the period of use. of the supplement has ended.
According to the study, after 90 days of treatment and close monitoring for 9 months after the end of administration, a 90% reduction in streptococcal pharyngitis episodes was found in children aged 3 to 10 years. Also, the little ones who received Blis K12 had a lower number of tracheitis (95%), viral pharyngitis (90%), rhinitis (89%), flu (87%), laryngitis (98%), acute otitis medium (100%) and stomatitis (75%). The study of Dr. Francesco di Piero was conducted on a sample of 124 female and male children, aged between 3 and 10 years.
They were divided into 2 groups: the treatment group – consisting of 48 children who had suffered from streptococcal pharyngitis in the previous year and who received treatment with Blis K12 – and the control group – consisting of children who did not have episodes of streptococcal pharyngitis in the previous year and who received placebo treatment.
Although it is not the first time that the beneficial effects of Loroblis have been supported by research, this is the first clinical study to show that the results are sustained in the long term, even after stopping treatment. How does this information help us?
These studies again confirm the medium- and long-term effectiveness of Loroblis, the supplement whose essential tablets contain Streptococcus salivarius K12. Intended for children over 3 years of age and adults, Loroblis contributes to both the prevention and control of respiratory infections caused by beta-hemolytic group A streptococcus, improving patients’ lives both during and after treatment.